GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Recovery of cardiac function following COVID ‐19 –  ECHOVID ‐19: a prospective longitudinal cohort study
    Wiley ; 2021
    In:  European Journal of Heart Failure Vol. 23, No. 11 ( 2021-11), p. 1903-1912
    Details
    In: European Journal of Heart Failure, Wiley, Vol. 23, No. 11 ( 2021-11), p. 1903-1912
    Abstract: The degree of cardiovascular sequelae following COVID‐19 remains unknown. The aim of this study was to investigate whether cardiac function recovers following COVID‐19. Methods and results A consecutive sample of patients hospitalized with COVID‐19 was prospectively included in this longitudinal study. All patients underwent an echocardiographic examination during hospitalization and 2 months later. All participants were successfully matched 1:1 with COVID‐19‐free controls by age and sex. A total of 91 patients were included (mean age 63 ± 12 years, 59% male). A median of 77 days (interquartile range: 72–92) passed between the two examinations. Right ventricular (RV) function improved following resolution of COVID‐19: tricuspid annular plane systolic excursion (TAPSE) (2.28 ± 0.40 cm vs. 2.11 ± 0.38 cm, P   〈  0.001) and RV longitudinal strain (RVLS) (25.3 ± 5.5% vs. 19.9 ± 5.8%, P   〈  0.001). In contrast, left ventricular (LV) systolic function assessed by global longitudinal strain (GLS) did not significantly improve (17.4 ± 2.9% vs. 17.6 ± 3.3%, P  = 0.6). N‐terminal pro‐B‐type natriuretic peptide decreased between the two examinations [177.6 (80.3–408.0) ng/L vs. 11.7 (5.7–24.0) ng/L, P   〈  0.001]. None of the participants had elevated troponins at follow‐up compared to 18 (27.7%) during hospitalization. Recovered COVID‐19 patients had significantly lower GLS (17.4 ± 2.9% vs. 18.8 ± 2.9%, P   〈  0.001 and adjusted P  = 0.004), TAPSE (2.28 ± 0.40 cm vs. 2.67 ± 0.44 cm, P   〈  0.001 and adjusted P   〈  0.001), and RVLS (25.3 ± 5.5% vs. 26.6 ± 5.8%, P  = 0.50 and adjusted P   〈  0.001) compared to matched controls. Conclusion Acute COVID‐19 affected negatively RV function and cardiac biomarkers but recovered following resolution of COVID‐19. In contrast, the observed reduced LV function during acute COVID‐19 did not improve post‐COVID‐19. Compared to the matched controls, both LV and RV function remained impaired.
    Type of Medium: Online Resource
    ISSN: 1388-9842 , 1879-0844
    URL: Issue
    URL: Article
    DOI: 10.1002/ejhf.v23.11
    DOI: 10.1002/ejhf.2347
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 1500332-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Electronic nudges to increase influenza vaccination uptake among patients with heart failure: A pre‐specified analysis of the NUDGE‐FLU trial
    Wiley ; 2023
    In:  European Journal of Heart Failure Vol. 25, No. 8 ( 2023-08), p. 1450-1458
    Details
    In: European Journal of Heart Failure, Wiley, Vol. 25, No. 8 ( 2023-08), p. 1450-1458
    Abstract: Seasonal influenza vaccination is strongly recommended in patients with heart failure (HF). The NUDGE‐FLU trial recently found two electronic behavioural nudging letter strategies – a letter highlighting potential cardiovascular benefits of vaccination and a repeated letter at day 14 –effective in increasing influenza vaccination in Denmark. The aims of this pre‐specified analysis was to further examine vaccination patterns and effects of these behavioural nudges in patients with HF including potential off‐target effects on guideline‐directed medical therapy (GDMT) use. Methods and results The nationwide NUDGE‐FLU trial randomized 964 870 Danish citizens ≥65 years to usual care or nine different electronic nudging letter strategies. Letters were delivered through the official Danish electronic letter system. The primary endpoint was the receipt of an influenza vaccine; additional outcomes for this analysis included GDMT use. In this analysis, we also assessed influenza vaccination rates in the overall Danish HF population including those 〈 65 years ( n  = 65 075). During the 2022–2023 season, influenza vaccination uptake was 71.6% in the overall Danish HF population but this varied considerably with only 44.6% uptake in those 〈 65 years. A total of 33 109 NUDGE‐FLU participants had HF at baseline. Vaccination uptake was higher among those on higher levels of baseline GDMT (≥3 classes: 85.3% vs. ≤2 classes: 81.9%; p   〈  0.001). HF status did not modify the effects of the two overall successful nudging strategies on influenza vaccination uptake (cardiovascular gain‐framed letter: p interaction  = 0.37; repeated letter: p interaction  = 0.55). No effect modification was observed across GDMT use levels for the repeated letter ( p interaction  = 0.88), whereas a trend towards attenuated effect among those on low levels of GDMT was observed for the cardiovascular gain‐framed letter ( p interaction  = 0.07). The letters had no impact on longitudinal GDMT use. Conclusions Approximately one in four patients with HF did not receive influenza vaccination with a pronounced implementation gap in those 〈 65 years where less than half were vaccinated. HF status did not modify the effectiveness of cardiovascular gain‐framed and repeated electronic nudging letters in increasing influenza vaccination rates. No unintended negative effects on longitudinal GDMT use were observed. Clinical Trial Registration: ClinicalTrials.gov NCT05542004.
    Type of Medium: Online Resource
    ISSN: 1388-9842 , 1879-0844
    URL: Issue
    URL: Article
    DOI: 10.1002/ejhf.v25.8
    DOI: 10.1002/ejhf.2913
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 1500332-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta‐analysis
    Wiley ; 2023
    In:  European Journal of Heart Failure
    Details
    In: European Journal of Heart Failure, Wiley
    Abstract: Randomized controlled trials (RCTs) enrolling patients at high cardiovascular risk have found that influenza vaccination may reduce the incidence of cardiovascular events. We performed an updated meta‐analysis assessing the effect of influenza vaccination on the incidence of cardiovascular events in patients with ischaemic heart disease or heart failure. Methods and results We searched PubMed, EMBASE and other sources to identify RCTs examining the effect of influenza vaccination on the incidence of cardiovascular events assessed as efficacy outcomes in patients with ischaemic heart disease or heart failure. Eligible studies followed patients for at least one influenza season, defined as a minimum duration of 6 months. The primary endpoint was a composite of cardiovascular death, acute coronary syndrome, stent thrombosis or coronary revascularization, stroke or heart failure hospitalization. The secondary endpoints were cardiovascular death and all‐cause death. Two investigators independently identified and extracted data from studies. Results were compared using hazard ratios (HRs) in both random effects and fixed effects models. We included five peer‐reviewed and one non peer‐reviewed RCTs for a total of 9340 patients. Five trials included patients with ischaemic heart disease ( n  = 4211) and one trial included patients with heart failure ( n  = 5129). Influenza vaccination was associated with a reduced incidence of the primary composite endpoint (random effects HR [rHR] 0.74, 95% confidence interval [CI] 0.63–0.88, p   〈  0.001, I 2  = 52%), cardiovascular death (rHR 0.63, 95% CI 0.42–0.95, p  = 0.028, I 2  = 58%) and all‐cause death (rHR 0.72, 95% CI 0.54–0.95, p  = 0.0227, I 2  = 52%). Results were similar when non peer‐reviewed data were excluded. Conclusion In this meta‐analysis of available RCTs in patients at high cardiovascular risk, influenza vaccination was associated with a reduced incidence of cardiovascular events, cardiovascular death and all‐cause death as compared to placebo or no treatment.
    Type of Medium: Online Resource
    ISSN: 1388-9842 , 1879-0844
    URL: Article
    DOI: 10.1002/ejhf.2945
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 1500332-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Echocardiographic abnormalities and predictors of mortality in hospitalized COVID‐19 patients: the ECHOVID‐19 study
    Wiley ; 2020
    In:  ESC Heart Failure Vol. 7, No. 6 ( 2020-12), p. 4189-4197
    Details
    In: ESC Heart Failure, Wiley, Vol. 7, No. 6 ( 2020-12), p. 4189-4197
    Abstract: The present study had two aims: (i) compare echocardiographic parameters in COVID‐19 patients with matched controls and (2) assess the prognostic value of measures of left (LV) and right ventricular (RV) function in relation to COVID‐19 related death. Methods and results In this prospective multicentre cohort study, 214 consecutive hospitalized COVID‐19 patients underwent an echocardiographic examination (by pre‐determined research protocol). All participants were successfully matched 1:1 with controls from the general population on age, sex, and hypertension. Mean age of the study sample was 69 years, and 55% were male participants. LV and RV systolic function was significantly reduced in COVID‐19 cases as assessed by global longitudinal strain (GLS) (16.4% ± 4.3 vs. 18.5% ± 3.0, P   〈  0.001), tricuspid annular plane systolic excursion (TAPSE) (2.0 ± 0.4 vs. 2.6 ± 0.5, P   〈  0.001), and RV strain (19.8 ± 5.9 vs. 24.2 ± 6.5, P  = 0.004). All parameters remained significantly reduced after adjusting for important cardiac risk factors. During follow‐up (median: 40 days), 25 COVID‐19 cases died. In multivariable Cox regression reduced TAPSE [hazard ratio (HR) = 1.18, 95% confidence interval (CI) [1.07–1.31], P  = 0.002, per 1 mm decrease], RV strain (HR = 1.64, 95%CI[1.02;2.66] , P  = 0.043, per 1% decrease) and GLS (HR = 1.20, 95%CI[1.07–1.35], P  = 0.002, per 1% decrease) were significantly associated with COVID‐19‐related death. TAPSE and GLS remained significantly associated with the outcome after restricting the analysis to patients without prevalent heart disease. Conclusions RV and LV function are significantly impaired in hospitalized COVID‐19 patients compared with matched controls. Furthermore, reduced TAPSE and GLS are independently associated with COVID‐19‐related death.
    Type of Medium: Online Resource
    ISSN: 2055-5822 , 2055-5822
    URL: Issue
    URL: Article
    DOI: 10.1002/ehf2.v7.6
    DOI: 10.1002/ehf2.13044
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2814355-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Effects of high‐dose versus standard‐dose quadrivalent influenza vaccine among patients with diabetes: A post‐hoc analysis of the DANFLU ‐1 trial
    Wiley ; 2024
    In:  Diabetes, Obesity and Metabolism Vol. 26, No. 5 ( 2024-05), p. 1821-1829
    Details
    In: Diabetes, Obesity and Metabolism, Wiley, Vol. 26, No. 5 ( 2024-05), p. 1821-1829
    Abstract: High‐dose quadrivalent influenza vaccine (QIV‐HD) has been shown to be more effective than standard‐dose (QIV‐SD) in reducing influenza infection, but whether diabetes status affects relative vaccine effectiveness (rVE) is unknown. We aimed to assess rVE on change in glycated haemoglobin [HbA1c (∆HbA1c)], incident diabetes, total all‐cause hospitalizations (first + recurrent), and a composite of all‐cause mortality and hospitalization for pneumonia or influenza. Methods DANFLU‐1 was a pragmatic, open‐label trial randomizing adults (65‐79 years) 1:1 to QIV‐HD or QIV‐SD during the 2021/22 influenza season. Cox proportional hazards regression was used to estimate rVE against incident diabetes and the composite endpoint, negative binomial regression to estimate rVE against all‐cause hospitalizations, and ANCOVA when assessing rVE against ∆HbA1c. Results Of the 12 477 participants, 1162 (9.3%) had diabetes at baseline. QIV‐HD, compared with QIV‐SD, was associated with a reduction in the rate of all‐cause hospitalizations irrespective of diabetes [overall: 647 vs. 742 events, incidence rate ratio (IRR): 0.87, 95% CI (0.76‐0.99); diabetes: 93 vs. 118 events, IRR: 0.80, 95% CI (0.55‐1.15); without diabetes: 554 vs. 624 events, IRR: 0.88, 95% CI (0.76‐1.01), p interaction = 0.62]. Among those with diabetes, QIV‐HD was associated with a lower risk of the composite outcome [2 vs. 11 events, HR: 0.18, 95% CI (0.04‐0.83)] but had no effect on ∆HbA1c; QIV‐HD adjusted mean difference: ∆ + 0.2 mmol/mol, 95% CI (−0.9 to 1.2). QIV‐HD did not affect the risk of incident diabetes [HR 1.18, 95% CI (0.94‐1.47)]. Conclusions In this post‐hoc analysis, QIV‐HD versus QIV‐SD was associated with an increased rVE against the composite of all‐cause death and hospitalization for pneumonia/influenza, and the all‐cause hospitalization rate irrespective of diabetes status.
    Type of Medium: Online Resource
    ISSN: 1462-8902 , 1463-1326
    URL: Issue
    URL: Article
    DOI: 10.1111/dom.v26.5
    DOI: 10.1111/dom.15498
    Language: English
    Publisher: Wiley
    Publication Date: 2024
    detail.hit.zdb_id: 2004918-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...